BioProcess International by informa

FACILITIES & CAPACITY | GLOBAL MARKETS | NEWS

Syngene expands global footprint with $36.5m Baltimore bet

The facility, previously owned by Emergent BioSolutions, will house a 50,000 L single-use bioreactor.



Shreeyashi Ojha, Reporter, BioProcess Insider
March 17, 2025

2 Min Read



DEPOSITPHOTOS/UniqueEye

Syngene International, the contract development and manufacturing organization (CDMO) arm of Biocon, has acquired a biologics site in Bayview, Baltimore, Maryland to manufacture monoclonal antibodies (mAbs).

PGR2026-00039
Biocon Ex.1074
Page 1 of 5

With a total investment of $50 million, including the cost of acquisition, Syngene aims to close the deal by the end of this month. The facility will be available for client projects in the second half of 2025.

“With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the US, this investment will enable Syngene to cater to growing client requirements in an expanding market,” said Peter Bains, CEO designate, Syngene International. “It will also provide clients, access to collective service capability of multiple geographic sites, scientists and experience.”

This marks the CDMO's first acquisition outside its home country, India. According to the firm, the Baltimore facility will provide US-based mAb developers direct access to onshore production.

Related: AstraZeneca shares vision of a green and AI-driven future

Deepak Jain, CFO of Syngene International said that the acquisition is not expected to have a significant impact on the financial guidance for the 2024-2025 fiscal year.“In the short term, we expect minor dilution of operating margins as a result of costs to be incurred in this facility.”

Under the agreement, Emergent retains the right to secure future manufacturing capacity at the facility, offering offtake potential for US-based innovators. The site will also support the growing animal health segment, where a US location is often a key client requirement.

As part of its restructuring plan, Emergent BioSolutions cut around 300 jobs, and shut down its facilities in Bayview and Rockville, Maryland in May 2024. The firm’s second facility in Camden, Baltimore has often faced regulatory scrutiny from the US Food and Drug Administration (FDA) in the past. Emergent sold this plant to Bora Pharmaceuticals for $30 million, in June 2024.

Speaking on the subject, a Syngene spokesperson confirmed that the Bayview facility has been approved by the FDA and is now being repurposed from a vaccine site to a mAb facility.

Read more about:

India

PGR2026-00039
Biocon Ex.1074
Page 2 of 5

About the Author



Shreeyashi Ojha

Reporter, BioProcess Insider

Journalist covering the manufacturing and processing sectors for biopharmaceuticals globally.

Originally from India, I am a Londoner at heart. I have recently graduated from Goldsmiths, University

Recommendations



Eli Lilly to build GLP-focused $6bn manufacturing facility in Alabama

by Millie Hoe

DEC 10, 2025

PGR2026-00039
Biocon Ex.1074
Page 3 of 5



GSK announces 5-year plan to invest $30bn in US

by Josh Abbott



WuXi Biologics gains EMA approval at Ireland commercial manufacturing site

by Millie Hoe

PGR2026-00039
Biocon Ex.1074
Page 4 of 5



Defying gravity while defining medicine: Varda secures $187m for space-orbital laboratories

by Millie Hoe

JUL 15, 2025

PGR2026-00039
Biocon Ex.1074
Page 5 of 5